US 12,352,764 B2
Method of detecting heart failure, device for detecting heart failure, sandwich immunoassay method, and combination of antibodies
Tomohiko Uda, Ibaraki (JP); Saeko Kitayama, Ibaraki (JP); and Kenyo Ishii, Ibaraki (JP)
Assigned to KYORITSU SEIYAKU CORPORATION, Tokyo (JP)
Appl. No. 17/046,819
Filed by KYORITSU SEIYAKU CORPORATION, Tokyo (JP)
PCT Filed Apr. 12, 2019, PCT No. PCT/JP2019/015992
§ 371(c)(1), (2) Date Oct. 12, 2020,
PCT Pub. No. WO2019/198822, PCT Pub. Date Oct. 17, 2019.
Claims priority of application No. 2018-077708 (JP), filed on Apr. 13, 2018.
Prior Publication US 2021/0148934 A1, May 20, 2021
Int. Cl. G01N 33/68 (2006.01); G01N 33/543 (2006.01)
CPC G01N 33/6893 (2013.01) [G01N 33/54306 (2013.01); G01N 2333/58 (2013.01); G01N 2800/325 (2013.01)] 10 Claims
OG exemplary drawing
 
1. A method of detecting heart failure from a sample collected from an organism, the method comprising the step of:
capturing NT-proANP or a fragment thereof contained in the sample using a first antibody for which a first epitope lies on any site among positions 31 to 67 of an amino acid sequence of NT-proANP;
adding a second antibody for labeling for which a second epitope lies on any site among positions 31 to 67 of the amino acid sequence of NT-proANP;
measuring a level of NT-proANP or a fragment thereof in the sample; and
detecting heart failure based on the level of NT-proANP or a fragment thereof in the sample,
wherein each of antibody A, antibody B and antibody C comprises a heavy chain variable domain (VH) and a light chain variable domain (VL), and each VH and VL comprises three complimentary determining regions (CDR), CDR1, CDR2, and CDR3;
wherein antibody A comprises a VH having CDR1 as set forth in SEQ ID NO: 5, CDR2 as set forth in SEQ ID NO:6, and CDR3 as set forth in SEQ ID NO:7, and a VL having CDR1 as set forth in SEQ ID NO:8, CDR2 as set forth in SEQ ID NO: 9, and CDR3 as set forth in SEQ ID NO:10;
wherein antibody B comprises a VH having CDR1 as set forth in SEQ ID NO: 15, CDR2 as set forth in SEQ ID NO:16 and CDR3 is VY and a VL having CDR1 as set forth in SEQ ID NO:18, CDR2 as set forth in SEQ ID NO:19, and CDR3 as set forth in SEQ ID NO:20;
wherein antibody C comprises a VH having CDR1 as set forth in SEQ ID NO: 25, CDR2 as set forth in SEQ ID NO:26, and CDR3 as set forth in SEQ ID NO: 27, and a VL having CDR1 as set forth in SEQ ID NO:28, CDR2 as set forth in SEQ ID NO:29; and CDR3 as set forth in SEQ ID NO:30; and
wherein the first antibody and second antibody are each selected from the group consisting of antibody A, antibody B and antibody C, and the first antibody is different from the second antibody.